Cargando…

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient

Detalles Bibliográficos
Autores principales:	Iwata, Hiroji, Saji, Shigehira, Ikeda, Masahiko, Inokuchi, Masashi, Uematsu, Takayoshi, Toyama, Tatsuya, Horii, Rie, Yamauchi, Chikako
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213548/ https://www.ncbi.nlm.nih.gov/pubmed/34009600 http://dx.doi.org/10.1007/s12282-021-01253-w

Ejemplares similares

The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient
por: Iwata, Hiroji, et al.
Publicado: (2019)

The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition
por: Yamauchi, Chikako, et al.
Publicado: (2019)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition
por: Yamauchi, Chikako, et al.
Publicado: (2021)

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
por: Uematsu, Takayoshi, et al.
Publicado: (2019)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
por: Uematsu, Takayoshi, et al.
Publicado: (2021)

The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
por: Inokuchi, Masafumi, et al.
Publicado: (2019)

Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
por: Inokuchi, Masafumi, et al.
Publicado: (2021)

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
por: Shimoi, Tatsunori, et al.
Publicado: (2020)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition
por: Nomura, Tsunehisa, et al.
Publicado: (2023)

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
por: Terada, Mitsuo, et al.
Publicado: (2023)

Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy
por: Honma, Naoko, et al.
Publicado: (2015)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society
por: Kawate, Takahiko, et al.
Publicado: (2021)

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
por: Ishiguro, Hiroshi, et al.
Publicado: (2017)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020)

Shoot, Edit, Share
por: Johnson, Kirsten, et al.
Publicado: (2016)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Impact of body mass index on breast cancer in accordance with the life-stage of women
por: Suzuki, Reiko, et al.
Publicado: (2012)

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
por: Iwamoto, Takayuki, et al.
Publicado: (2019)

Japanese gastric cancer treatment guidelines 2018 (5th edition)
Publicado: (2020)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
por: Toi, Masakazu, et al.
Publicado: (2010)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
por: Ogiya, Rin, et al.
Publicado: (2017)

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7
por: Suga, Junko, et al.
Publicado: (2018)

Trend in Cancer Incidence and Mortality in Fukushima From 2008 Through 2015
por: Shibata, Akiko, et al.
Publicado: (2021)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
por: Ueno, Takayuki, et al.
Publicado: (2016)

Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
por: Okumura, Naoki, et al.
Publicado: (2002)

Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol
por: Saji, Shigehira, et al.
Publicado: (1999)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients
por: Toyama, Tatsuya, et al.
Publicado: (2007)

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network
por: Kiso, Marina, et al.
Publicado: (2018)

Shared genetic components between metabolic syndrome and schizophrenia: Genetic correlation using multipopulation data sets
por: Aoki, Rei, et al.
Publicado: (2022)

“The kind of doctor who doesn't believe doctor knows best”: Doctors for Choice and the Medical Voice in Irish Abortion Politics, 2002-2018
por: Bergen, Sadie
Publicado: (2022)

Attitudes of Indonesian Medical Doctors and Medical Students Toward Genome Editing
por: Izzah, Safira Nur, et al.
Publicado: (2021)

Diagnostic accuracy of the attenuation value in abdominal contrast enhanced dynamic multi-detector-row computed tomography for esophageal varices in patients with liver cirrhosis
por: Inokuchi, Yasuhiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l8attbamunm7qcnbdua86fg6hk